D.E. Shaw & Co
TVTX icon

D.E. Shaw & Co’s Travere Therapeutics TVTX Stock Holding History

D.E. Shaw & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.9M Sell
836,544
-258,012
-24% -$7.71M 0.01% 1014
2025
Q4 		$41.8M Buy
1,094,556
+431,304
+65% +$14M 0.02% 802
2025
Q3 		$15.9M Sell
663,252
-467,498
-41% -$8.79M 0.01% 1344
2025
Q2 		$16.7M Sell
1,130,750
-582,842
-34% -$9.66M 0.01% 1148
2025
Q1 		$30.7M Sell
1,713,592
-564,783
-25% -$11.5M 0.03% 707
2024
Q4 		$39.7M Buy
2,278,375
+438,306
+24% +$7.75M 0.03% 672
2024
Q3 		$25.7M Buy
1,840,069
+306,997
+20% +$3.2M 0.02% 856
2024
Q2 		$12.6M Sell
1,533,072
-311,591
-17% -$2.1M 0.01% 1185
2024
Q1 		$14.2M Buy
1,844,663
+186,516
+11% +$1.57M 0.01% 1135
2023
Q4 		$14.9M Buy
1,658,147
+674,602
+69% +$4.91M 0.01% 1113
2023
Q3 		$8.79M Sell
983,545
-277,459
-22% -$3.92M 0.01% 1374
2023
Q2 		$19.4M Buy
1,261,004
+261,513
+26% +$4.76M 0.02% 886
2023
Q1 		$22.5M Buy
999,491
+532,651
+114% +$11.3M 0.02% 823
2022
Q4 		$9.82M Buy
466,840
+90,997
+24% +$1.93M 0.01% 1447
2022
Q3 		$9.26M Sell
375,843
-52,984
-12% -$1.37M 0.01% 1424
2022
Q2 		$10.4M Sell
428,827
-46,574
-10% -$1.17M 0.01% 1361
2022
Q1 		$12.3M Buy
475,401
+128,060
+37% +$3.4M 0.01% 1421
2021
Q4 		$10.8M Sell
347,341
-58,496
-14% -$1.65M 0.01% 1602
2021
Q3 		$9.84M Sell
405,837
-791,961
-66% -$14.6M 0.01% 1538
2021
Q2 		$17.5M Sell
1,197,798
-278,681
-19% -$5.5M 0.02% 1096
2021
Q1 		$36.9M Sell
1,476,479
-67,363
-4% -$1.86M 0.04% 626
2020
Q4 		$42.1M Sell
1,543,842
-109,196
-7% -$2.55M 0.04% 572
2020
Q3 		$30.5M Sell
1,653,038
-130,094
-7% -$2.53M 0.03% 623
2020
Q2 		$36.4M Buy
1,783,132
+196,601
+12% +$3.13M 0.04% 491
2020
Q1 		$23.1M Buy
1,586,531
+143,959
+10% +$2.17M 0.04% 559
2019
Q4 		$20.5M Buy
1,442,572
+298,532
+26% +$3.81M 0.02% 806
2019
Q3 		$13.3M Buy
1,144,040
+252,373
+28% +$4.17M 0.02% 994
2019
Q2 		$17.9M Buy
891,667
+33,078
+4% +$653K 0.02% 807
2019
Q1 		$19.4M Buy
858,589
+81,069
+10% +$1.79M 0.03% 739
2018
Q4 		$17.6M Buy
777,520
+182,318
+31% +$4.54M 0.02% 768
2018
Q3 		$17.1M Buy
595,202
+76,174
+15% +$2.18M 0.02% 839
2018
Q2 		$14.1M Buy
519,028
+119,500
+30% +$3.18M 0.02% 903
2018
Q1 		$8.93M Buy
399,528
+104,586
+35% +$2.49M 0.01% 1060
2017
Q4 		$6.21M Buy
294,942
+135,761
+85% +$3.1M 0.01% 1344
2017
Q3 		$3.96M Buy
159,181
+117,425
+281% +$2.59M 0.01% 1542
2017
Q2 		$809K Sell
41,756
-46,503
-53% -$843K ﹤0.01% 2539
2017
Q1 		$1.63M Buy
88,259
+30,540
+53% +$597K ﹤0.01% 1972
2016
Q4 		$1.09M Buy
57,719
+23,219
+67% +$475K ﹤0.01% 2404
2016
Q3 		$772K Sell
34,500
-9,686
-22% -$184K ﹤0.01% 2563
2016
Q2 		$787K Buy
44,186
+16,577
+60% +$268K ﹤0.01% 2555
2016
Q1 		$377K Buy
+27,609
New +$419K ﹤0.01% 2919
2015
Q3 		– Sell
-33,619
Closed -$1.11M – 3901
2015
Q2 		$1.11M Sell
33,619
-6,081
-15% -$167K ﹤0.01% 2627
2015
Q1 		$951K Sell
39,700
-5,900
-13% -$90K ﹤0.01% 2592
2014
Q4 		$558K Buy
45,600
+24,200
+113% +$250K ﹤0.01% 3244
2014
Q3 		$193K Buy
21,400
+7,600
+55% +$89.4K ﹤0.01% 3901
2014
Q2 		$162K Buy
13,800
+3,665
+36% +$49.7K ﹤0.01% 4031
2014
Q1 		$216K Buy
+10,135
New +$156K ﹤0.01% 4054

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's TVTX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Travere Therapeutics (TVTX) stake by 24% in Q1 2026, selling an estimated $7.71M and leaving 836,544 shares worth $24.9M. The position accounts for 0.01% of the portfolio, ranked #1014.

D.E. Shaw & Co first reported a position in TVTX in Q1 2014 and has held it in 47 quarters since. The position peaked at $42.1M in Q4 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • D.E. Shaw & Co held 836,544 shares of Travere Therapeutics worth $24.9M as of Q1 2026.
  • D.E. Shaw & Co sold 258,012 Travere Therapeutics shares in Q1 2026, an estimated $7.71M.
  • Travere Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1014 holding.
  • D.E. Shaw & Co first reported a position in Travere Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • D.E. Shaw & Co's Travere Therapeutics position peaked at $42.1M in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.